Latest
11:04
10:55
10:50
10:26
10:20
08:05
【IMMUNEONCO-B (01541.HK): Subsidiary Yiming Kaier receives RMB 50 million capital increase from Shengke Qihang and other investors; Company to hold approximately 68.34% upon completion】NewTimeSpace News: IMMUNEONCO-B (01541.HK): The Company's non-wholly-owned subsidiary Yiming Kaier received a capital increase of RMB 50 million in total consideration from investors including Shengke Qihang, Xinjie Chuangyuan and Mr. Wang Xueyan, with the investors subscribing for approximately 15.83% of the enlarged equity; upon completion the Company will hold approximately 68.34%, the target company will remain a non-wholly-owned subsidiary, and the transaction is fully exempt from Chapter 14 of the Listing Rules.
Tag:
IMMUNEONCO-B01541.HK
07:57
【TRANSCENTA-B (06628.HK): Proposes disposal of CDMO assets for RMB 190 million to a WuXi Biologics subsidiary, focusing on innovative drug R&D as core business】NewTimeSpace News: TRANSCENTA-B (06628.HK): The Company's wholly-owned subsidiary proposes to dispose of its CDMO assets to a wholly-owned subsidiary of WuXi Biologics for RMB 190 million, with an estimated loss of approximately RMB 280 million to be recognised; the transaction constitutes a major transaction subject to shareholders' approval, with the circular expected to be despatched on or before 25 August 2026.
Tag:
TRANSCENTA-B06628.HK
07:54
【OCT (ASIA) (03366.HK): Proposes disposal of 100% equity interest in OCT (Huizhou) via public listing for RMB 306,732,900; EGM to be held on 21 August】NewTimeSpace News: OCT (ASIA) (03366.HK): The Company proposes to dispose of the 100% equity interest in OCT (Huizhou) Industrial Park Management Co., Ltd. through a public listing for a final consideration of RMB 306,732,900, with Shenghong Technology (Huizhou) Co., Ltd. as the purchaser; the target property was valued at approximately RMB 280 million, representing an appreciation of approximately RMB 154 million over book value; an EGM will be held on 21 August 2026.
Tag:
OCT (ASIA)03366.HK